Low-dose methotrexate - A therapeutical kick in TNF-alpha antagonist treatment for recalcitrant psoriasis vulgaris

Dermatologic Therapy

Volumn 27, Issue 1, 2014, Pages 55-59

  Wilsmann Theis, Dagmar ^a   Fronhoffs, Kristina ^a   Ehler, Lin Kristin ^a   Wenzel, Joerg ^a   Bieber, Thomas ^a   Klingmueller, Karin ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

methotrexate; psoriasis vulgaris; TNF alpha inhibitor

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; FUMARIC ACID; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CREATININE BLOOD LEVEL; DACTYLITIS; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTRANSAMINASEMIA; LOW DRUG DOSE; MALE; MIDDLE AGED; MONOTHERAPY; MORNING STIFFNESS; NAUSEA; PANCREATITIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PUVA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

METHOTREXATE; PSORIASIS VULGARIS; TNF-ALPHA INHIBITOR;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84893546535     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/dth.12046     Document Type: Article

References (14)

1. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001: 137 (3): 280-284.
2. Kanwar AJ, Yadav S, Dogra S,. Psoriasis: what is new in nonbiologic systemic therapy in the era of biologics? Indian J Dermatol Venereol Leprol 2010: 76 (6): 622-633.
3. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998: 41 (9): 1552-1563.
4. Lee YH, Woo JH, Rho YH, et al. Meta-analysis of the combination of TNF inhibitor plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. Rheumatol Int 2007: 28 (6): 553-559.
5. Daly M, Alikhan A, Armstrong AWJ,. Combination systemic therapies in psoriatic arthritis. J Dermatolog Treat 2011: 22 (5): 276-284.
6. Gisondi P, Del Giglio M, Cotena C, et al. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol 2008: 158 (6): 1345-1349.
7. Warren RB, Brown BC, Lavery D, et al. Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre. Br J Dermatol 2009: 160 (1): 162-169.
8. Yamauchi PS, Lowe NJ,. Etanercept therapy allows the tapering of methotrexate and sustained clinical responses in patients with moderate to severe psoriasis. Int J Dermatol 2008: 47 (2): 202-204.
9. Zachariae C, Mørk NJ, Reunala T, et al. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol 2008: 88 (5): 495-501.
10. Gisondi P, Del Giglio M, Cozzi A, et al. Psoriasis, the liver, and the gastrointestinal tract. Dermatol Ther 2010: 23 (2): 155-159.
11. Ortonne JP, Taïeb A, Ormerod AD, et al. Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept. Br J Dermatol 2009: 161 (5): 1190-1195.
12. Gottlieb AB, Langley RG, Strober BE, et al. Randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol 2012: 25: 1365-2133.
13. Jensen P, Skov L, Zachariae C,. Systemic combination treatment for psoriasis: a review. Acta Derm Venereol 2010: 90 (4): 341-349.
14. Wolbink GJ, Aarden LA, Dijkmans BA,. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol 2009: 21: 211-215.